Medicine & healthcare

Study: Finger-Prick Blood Test Validated for Alzheimer’s Biomarkers

Does finger-prick blood testing meaningfully expand access to Alzheimer’s screening, or are key clinical and implementation questions still unresolved?

Published JAN 8

Study: Finger-Prick Blood Test Validated for Alzheimer’s Biomarkers

Story

Above: MRI scan showing early signs of Alzheimer’s disease in London, U.K., on May 30, 2025. Image credit: Peter Dazeley/Getty Images

The Facts

Researchers from the University of Gothenburg and multiple European centers have reportedly conducted the first large-scale validation of a finger-prick blood test for Alzheimer’s biomarkers, which is claimed to be accessible “independent of geographical proximity to specialized healthcare infrastructure.”
Nature
University of Gothenburg
Eric Topol on X
The study, published Monday in Nature Medicine as part of the DROP-AD (Dried Blood Spot for Alzheimer’s Disease) project, involved 337 participants from seven medical centers across Europe, including individuals who were cognitively unimpaired, had cognitive impairment or dementia, and a group of 31 people with Down syndrome.
Nature
Inside Precision Medicine
University of Gothenburg
Using finger-prick samples applied to filter paper, capillary dried blood spot testing for p-tau217 showed 86% accuracy — considered "good discrimination" — in predicting Alzheimer’s-related changes in cerebrospinal fluid, compared to roughly 98% for standard venous blood tests.
Today's Clinical Lab
Inside Precision Medicine
The dried blood samples also successfully measured glial fibrillary acidic protein and neurofilament light, two additional biomarkers linked to brain inflammation and neurodegeneration, with reportedly "strong agreement" to standard blood tests.
Healthday
University of Gothenburg
According to the study, the test has potential for at-home use, as participants in the Exeter cohort were able to successfully self-collect capillary blood samples after observing trained staff and receiving written instructions. Samples remained stable during storage and shipment at room temperature.
Nature
News Medical
Exeter Biomedical Research Centre
Researchers noted that while the method shows promise for research and population screening, “further methodological refinement and validation" is needed before clinical use, as collection failures occurred in 15 to 25% of cases.
Inside Precision Medicine
Psychiatric News
News Medical

Sources Split

LEFT

CENTER

RIGHT

ESTAB
CRIT

CENTER

PRO
ESTAB

The Spin

Techno-optimist narrative

The DROP-AD study signals a practical breakthrough in Alzheimer’s detection by validating finger-prick dried blood spot testing for key biomarkers, including p-tau217, GFAP and NfL. By enabling accurate, room-temperature samples that can be self-collected and mailed, the approach could make screening faster, cheaper and widely accessible — supporting earlier identification, earlier treatment pathways and large-scale population monitoring. The test also has potential for other neurodegenerative diseases such as Parkinson’s, ALS and MS.

NIHR Manchester Clinical Research Facility

Ace Alzheimer Center Barcelona on X

Techno-skeptic narrative

While the DROP-AD findings are promising, past experience with Alzheimer’s blood tests urges caution. Earlier commercial screeners have shown high false-positive rates, and major groups like the Alzheimer’s Association caution that blood biomarkers cannot yet stand alone for diagnosis. Experts note that accuracy, interpretation, disclosure and real-world implementation — especially in primary care — require further validation before widespread clinical use.